Oral Bacteria Linked to Alzheimer's: How Gum Disease Affects Brain Health

A pharmaceutical company looked at the brains of Alzheimer’s patients and found something that shouldn’t be there: bacteria from the mouth. Not in a few samples — in the majority of them. And the toxic enzymes those bacteria produce? Their levels correlated directly with the severity of the disease. That finding launched a drug development program targeting those specific enzymes — and it should change how you think about bleeding gums.

What’s actually happening

The 2019 study published in Science Advances by Dominy et al. examined postmortem brain tissue from Alzheimer’s patients and found Porphyromonas gingivalis — the keystone pathogen in chronic gum disease — in the majority of samples. They also found gingipains, the toxic proteases P. gingivalis produces, and the levels of those gingipains correlated with both tau pathology and amyloid accumulation. The more gingipain, the worse the Alzheimer’s.

When researchers infected mice with P. gingivalis orally, the bacteria colonized their brains. Amyloid-beta production increased. Neuroinflammation accelerated. Neurons in the hippocampus — the brain region critical for memory and the first to degenerate in Alzheimer’s — were damaged.

Then came the critical experiment: researchers treated the infected mice with small-molecule inhibitors designed to block gingipain activity. Bacterial load in the brain decreased. Amyloid production dropped. Neuroinflammation reduced. Hippocampal neurons were rescued. That result was significant enough that the researchers moved the compound into clinical trials for mild to moderate Alzheimer’s disease.

We’ve covered how oral bacteria affect cognitive decline and the gut-brain research that established the communication pathway between your microbiome and your brain. The gingipain story takes it further: researchers aren’t just documenting the connection anymore. They’re building drugs to interrupt it.

Why this is happening to you specifically

Half of adults over 35 have some form of active periodontal disease. By your 60s and 70s, that climbs to 70–80 percent — not just surface inflammation, but actual bone loss around the teeth. And the early stages are almost entirely painless.

Your gums bleed when you brush. You rinse, spit, move on. That bleeding is your body signaling that the epithelial barrier between your oral bacteria and your circulatory system has broken down. P. gingivalis produces outer membrane vesicles — tiny structures small enough to cross the blood-brain barrier, carrying toxic enzymes directly into brain tissue. A 2024 review by Liu et al. in Critical Reviews in Microbiology mapped exactly how this works: the vesicles trigger neuroinflammation, disrupt the brain’s ion regulation, and accelerate the accumulation of amyloid plaques and tau tangles.

But the bloodstream route is only half the story. A 2025 study in the Journal of Dental Research found that P. gingivalis also travels through the digestive tract, causing gut microbiome dysbiosis and disrupting a metabolic pathway called kynurenine metabolism. Kynurenine metabolites directly regulate neuroinflammation and neuronal survival. When that pathway gets disrupted, a neurotoxic metabolite called 3-hydroxykynurenine spikes in the blood and hippocampus, suppresses a key neuroprotective gene, and triggers cell death in the brain.

The bacteria don’t even need to cross the blood-brain barrier directly. They wreck the gut, the gut wrecks the metabolic pathway, and the pathway wrecks the brain. That’s the oral-gut-brain axis — and it means your mouth has been talking to your brain this whole time. You just weren’t listening.

The pharmaceutical signal

The fact that a drug company invested in developing gingipain inhibitors for Alzheimer’s is itself meaningful. Pharmaceutical companies don’t spend millions on clinical trials for speculative biology. They do it when the mechanistic evidence is strong enough to justify the risk.

The compound — atuzaginostat — targets the gingipain enzymes directly. In animal models, blocking those enzymes reduced bacterial load, decreased amyloid production, and rescued neurons. That’s a clean mechanistic story: identify the toxic enzyme, block it, reduce the damage.

But here’s the uncomfortable truth the pharmaceutical angle reveals: we’re developing drugs to clean up damage that’s largely preventable. P. gingivalis doesn’t randomly appear in the brain. It gets there because periodontal disease gives it access — through inflamed gum tissue and a disrupted oral microbiome. If you prevent the oral infection, you prevent the bacterial access. You don’t need a gingipain inhibitor if the gingipains never reach your brain.

What you can do today

The research on prevention is encouraging. Treating periodontal disease reduces circulating inflammatory markers, including C-reactive protein and interleukin-6 — the same markers associated with cardiovascular disease, metabolic dysfunction, and cognitive decline.

Interdental cleaning is non-negotiable. Teeth have four surfaces. Brushing only reaches two. The spaces between teeth are where P. gingivalis preferentially colonizes — warm, nutrient-rich, and protected from immune surveillance. Flossing or a water flosser clears those spaces.

Get a periodontal assessment. Ask your dentist about pocket depths and bone levels at your next visit. If there’s bone loss or deepening pockets, ask for a referral to a periodontist. Standard twice-yearly cleanings may not be enough if you have active disease or risk factors.

Consider oral probiotics. A 2022 study found that probiotic lozenges enhanced oral immune response and shifted the oral microbiome toward healthier species. This is early research, but the mechanism makes sense: if dysbiosis drives the problem, rebalancing the microbiome addresses the root cause.

Reduce your total inflammatory burden. Everything that lowers systemic inflammation also protects your periodontal health — and vice versa. Diet, sleep, stress management, and gut health all affect how well your immune system contains a periodontal infection. The relationship is bidirectional: oral dysbiosis worsens gut health, and gut dysbiosis worsens oral health.

What we still don’t know

The biggest gap in the research: we don’t yet have a long-term human trial showing that treating gum disease directly slows cognitive decline. We know it reduces inflammatory markers. We know P. gingivalis correlates with Alzheimer’s pathology. We know the mechanisms are plausible and the animal data is compelling. But the specific clinical proof — “treat the gums, protect the brain” in a large human cohort over years — that trial hasn’t been completed yet.

The pharmaceutical angle raises its own question: if gingipain inhibitors work, do they work better than preventing oral dysbiosis in the first place? Blocking a toxic enzyme after it’s already in your brain is a reactive strategy. Preventing the bacteria from getting there is proactive. The research suggests both approaches are valid, but nobody’s compared them head-to-head.

The supplement question

If you’re going to supplement, focus on products that support the oral-gut-brain axis — oral probiotics for the microbiome at the source, and gut-brain probiotics for the downstream pathway.

BioGaia Prodentis Oral Probiotics — Probiotic lozenges designed to promote healthy gums and teeth by rebalancing the oral microbiome. Targets the starting point of the oral-gut-brain pathway.

Garden of Life Dr. Formulated Gut Brain Axis Microbiome Probiotics — Contains pre-, pro-, and postbiotics specifically targeting the gut-brain axis. Supports the downstream pathway oral bacteria exploit.

ProBiora Professional Strength Oral Probiotics — Professional-strength dental probiotic for teeth and gums. Targets the oral microbiome where P. gingivalis colonizes.

Disclosure: This post contains affiliate links. If you purchase through these links, I may earn a small commission at no extra cost to you.

What’s clear is that your mouth has been sending signals about your brain health for years. The question is whether you’re going to wait for a drug to address what’s already there — or start listening now.

Save for later — send to someone who dismisses bleeding gums as normal.